Omni Partners’s Sarepta Therapeutics SRPT Stock Holding History

Omni Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-42,576	Closed	-$1.44M	–	26
2017 Q2	$1.44M	Buy	+42,576	New	+$1.39M	0.18%	26

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Omni Partners's SRPT Position: Q3 2017 in Review

Omni Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2017, closing a stake of 42,576 shares — an estimated $1.44M sold.

Omni Partners first reported a position in SRPT in Q2 2017 and held it in 1 quarter. The position peaked at $1.44M in Q2 2017. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

Omni Partners reported no remaining Sarepta Therapeutics position as of Q3 2017 after selling out during the quarter.
Omni Partners sold 42,576 Sarepta Therapeutics shares in Q3 2017, an estimated $1.44M.
Omni Partners first reported a position in Sarepta Therapeutics in Q2 2017 and held it in 1 quarter.
Omni Partners's Sarepta Therapeutics position peaked at $1.44M in Q2 2017.
233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Omni Partners's 13F filing for Q3 2017, filed 13 Nov 2017.